公开(公告)号：WO2018044640A1

公开(公告)日：2018-03-08

申请号：PCT/US2017/048137

申请日：2017-08-23

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： CHALOTHORN, Dan ,  MORTON, Lori C.

IPC: C07K16/24 ,  A61K39/00

Abstract: The present invention provides anti-Gremlin-1 (GREM1) antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (PAH). It is disclosed a method of treating a subject having pulmonary arterial hypertension (PAH), comprising administering to the subject a therapeutically effective amount of an anti-gremlin-1 (GREM1) antibody, or antigen-binding fragment thereof, wherein the therapeutic effect of administration of the anti-GREMl antibody, or antigen-binding fragment thereof, to the subject is selected from the group consisting of inhibiting thickening of the pulmonary artery in the subject; increasing stroke volume in the subject; increasing right ventricle cardiac output in the subject; and extending survival time of the subject, thereby treating the subject having PAH.

Abstract translation: 本发明提供了抗Gremlin-1（GREM1）抗体及其抗原结合片段，以及使用这些抗体或其抗原结合片段用于治疗患有肺动脉高压（PAH）的受试者的方法。 公开了治疗患有肺动脉高压（PAH）的受试者的方法，该方法包括给予受试者治疗有效量的抗Gremlin-1（GREM1）抗体或其抗原结合片段，其中治疗效果为 向受试者施用抗GREM1抗体或其抗原结合片段选自：抑制受试者中肺动脉增厚; 增加受试者的每搏输出量; 增加受试者的右心室心输出量; 并延长受试者的存活时间，从而治疗患有PAH的受试者。

公开(公告)号：WO2023070097A2

公开(公告)日：2023-04-27

申请号：PCT/US2022/078530

申请日：2022-10-21

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： CHALOTHORN, Dan ,  MORTON, Lori ,  LAI, KehDih

IPC: A61K39/395 ,  C07K16/36 ,  A61K2039/505 ,  A61K2039/545 ,  A61K39/3955 ,  A61P7/02 ,  C07K2317/21 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present disclosure provides antibodies that bind to the A2 domain of Factor XI (FXI) and methods of using the same. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation via the intrinsic pathway without affecting hemostasis, as shown by their effect on prolonging aPTT without affecting PT. As such, these antagonist antibodies may be used to treat blood clotting diseases or disorders or treatment regimens that have clot formation as a risk factor, such as, but not limited to atrial fibrillation. In certain embodiments, the disclosure includes antibodies that bind FXI and mediate clot formation or thrombogenesis. The antibodies of the disclosure may be fully human, non-naturally occurring antibodies.

公开(公告)号：WO2020206139A1

公开(公告)日：2020-10-08

申请号：PCT/US2020/026413

申请日：2020-04-02

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： TANG, Yajun ,  CHALOTHORN, Dan ,  MITNAUL, Lyndon ,  MORTON, Lori ,  ZAMOLODCHIKOV, Daria ,  ALESSANDRI-HABER, Nicole ,  MACDONALD, Lynn

IPC: A01K67/027 ,  C07K14/745

Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized coagulation factor XII ( F12 ) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized F12 locus express a human coagulation factor XII protein or a chimeric coagulation factor XII protein, fragments of which are from human coagulation factor XII. Methods are provided for using such non-human animals comprising a humanized F12 locus to assess in vivo efficacy of human- coagulation-factor-XII-targeting reagents such as nuclease agents designed to target human F12 . A short isoform of F12 that is produced locally in the brain, and methods of using the short isoform, are also provide.

公开(公告)号：WO2020247812A1

公开(公告)日：2020-12-10

申请号：PCT/US2020/036412

申请日：2020-06-05

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： FANG, Qing ,  SIAO, Chia-Jen ,  CHALOTHORN, Dan ,  LAI, KehDih ,  SABIN, Leah ,  SATTLER, Rachel ,  ZAMBROWICZ, Brian ,  MORTON, Lori

IPC: A01K67/027 ,  C07K14/765

Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized albumin (ALB ) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non human animal cells or non-human animals comprising a humanized albumin locus express a human albumin protein or a chimeric albumin protein, fragments of which are from human albumin. Methods are provided for using such non-human animals comprising a humanized albumin locus to assess in vivo efficacy of human-albumin -targeting reagents such as nuclease agents designed to target human albumin.

公开(公告)号：WO2019246176A8

公开(公告)日：2019-12-26

申请号：PCT/US2019/037865

申请日：2019-06-19

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： CHALOTHORN, Dan ,  MORTON, Lori, C. ,  MITNAUL, Lyndon ,  LAI, KehDih

IPC: A61P7/02 ,  C07K16/36

Abstract: The present invention provides monoclonal antibodies that bind to the Factor XII (FXII) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to FXII and to the activated form of FXII (FXIIa). In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing FXII activity, thus providing a means of treating or preventing a disease, disorder or condition associated with thrombosis in humans.

公开(公告)号：WO2019246176A1

公开(公告)日：2019-12-26

申请号：PCT/US2019/037865

申请日：2019-06-19

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： CHALOTHORN, Dan ,  MORTON, Lori, C. ,  MITNAUL, Lyndon ,  LAI, Kehdih

IPC: A61P7/02 ,  C07K16/36

Abstract: The present invention provides monoclonal antibodies that bind to the Factor XII (FXII) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to FXII and to the activated form of FXII (FXIIa). In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing FXII activity, thus providing a means of treating or preventing a disease, disorder or condition associated with thrombosis in humans.

公开(公告)号：WO2018009732A1

公开(公告)日：2018-01-11

申请号：PCT/US2017/041000

申请日：2017-07-07

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： CHALOTHORN, Dan ,  MORTON, Lori, C.

IPC: A61K39/395 ,  C07K16/22 ,  A61P9/12

Abstract: The present invention provides anti-Activin A antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (PAH).

Abstract translation: 本发明提供了抗激活蛋白A抗体及其抗原结合片段，以及使用这些抗体或其抗原结合片段用于治疗患有肺动脉高压的受试者的方法 （PAH）。